ESCMID Pipeline Corner

ESCMID offers small innovative pharmaceutical companies with early-stage antimicrobial therapies in development a platform at ECCMID to present their products to a wider audience.

Health-I-Care Pipeline Corner at ECCMID 2019

ECCMID Pipeline Corner moderator: Alexander W. Friedrich, Netherlands & Corinna Glasner, Netherlands

  • Kristin Klar
    • Hand hygiene at German primary schools - first results of an interdisciplinary proje
  • Michel E. van der Rest
    • The development of a POCT rapid test technology to identify pan-resistant microorganisms
  • Erik Toonen
    • EcHECk - research on a fast and reliable test for the detection of EHEC infections
  • Heiman Wertheim
    • Easy to read agar screening plates to facilitate culture-guided antibiotic prophylaxis for prostate biopsies

Therapeutics Pipeline Corner at ECCMID 2019

ECCMID Pipeline Corner moderator: Ursula Theuretzbacher, Vienna, Austria

  • Procarta Biosystems, Andrew Lightfoot
  • Centauri Therapeutics, Jennifer Schneider
  • ContraFect Corporation, Raymond Schuch
  • Entasis Therapeutics, Manos Perros
  • Summit Therapeutics, Richard Vickers
  • Deinove, Georges Gaudriault
  • Combioxin, Samareh Lajaunias
  • SetLance, Alessandro Pini


Pipeline Corner at ECCMID 2019 in Amsterdam

ECCMID 2019 in Amsterdam will offer small innovative companies a platform to give an overview of their R&D pipelines and present recent advances in their early-stage products. 

Contact Ursula Theuretzbacher for more information.

Presenting companies 2018

ECCMID Pipeline Corner moderator: Ursula Theuretzbacher, Vienna, Austria

  • Antabio; Labège, France
  • VenatoRx Pharmaceuticals; Malvern PA, United States
  • Bugworks Research; Bangalore, India
  • Forge Therapeutics; San Diego CA, United States
  • Polyphor; Allschwil, Switzerland
  • Cube Dx; St. Valentin, Austria
  • Global Antibiotic Research & Development Partnership (GARDP)
  • European Investment Bank's Infectious Disease Finance Facility
  • Pew Trust's SPARK platform

Presenting companies at ECCMID 2017


•    AiCuris GmbH, Germany (ePoster only)
•    Allecra Therapeutics GmbH, Germany
•    Arsanis Biosciences, Austria/United States
•    Cantab Anti-infectives Ltd, United Kingdom
•    Centauri Therapeutics Ltd, United Kingdom (ePoster only)
•    Naicons Srl., Italy
•    NovaBiotics Ltd, United Kingdom
•    Phico Therapeutics Ltd, United Kingdom
•    Scynexis Inc., United States (ePoster only)
•    Septeos, France (ePoster only)
•    Synthetic Biologics Inc., United States
•    TAXIS Pharmaceuticals Inc., United States

Presenting companies ECCMID 2016

  • BioVersys, Switzerland
  • Melinta, United States
  • Deutsches Zentrum für Infektionsforschung, Germany
  • Discuva, United Kingdom
  • Cidara, United States
  • Spero, United States
  • ABAC Therapeutics, Spain
  • Biovertis, Germany
  • Nabriva, Austria
  • Vitas Pharma, India
Pipeline Corner at ECCMID 2015

The dedicated Pipeline Corner at ECCMID 2015 generated great interest among the research community, larger pharmaceutical companies, service providers, venture capital firms, and the press. The display of electronic posters has proved to be the starting point for promising discussions and meetings throughout the conference.

download press release

The posters can be found in our eLibrary under this link.

ESCMID Initiatives

Get an overview on ESCMID initiatives in the field of antimicrobial resistance, find out more about EUCAST, TROCAR, GRACE, ESGAP, ESGARS, ESGNI and ECCMID. The ESCMID PK/PD of Anti-Infectives Study Group (EPASG) is supporting the Pipeline Corner and Pipeline Talks at ECCMID.

Global initiatives

This list displays European or international initiatives active in combatting antimicrobial resistance by developing new compounds. If you would like to add a new European or international initiative or amend an existing entry, please contact the .

New Drugs for Bad Bugs

Driving reinvestment in R&D for antibiotics and advocating their responsible use

Longitude Prize

CDC Antibiotic Resistance Solutions Initiative

Joint Programme Initiative on Antimicrobial Resistance